Cannabis Bioscience Int'l Hldgs Inc (CBIH)

[HNDRXX]

$CHNC: DD Package PharmacologyUniversity, Merger Clinical Trials, Insider Ownership, "Multi-Million Dollar Contracts"



$CHNC Merged with the following company in 2019 Below. Insider ownership and employee stock benefit plans appeared to have soon followed which resulted into restricted shares. Articles for Merger Filed in August 2020



https://www.pri.center/
https://www.instagram.com/prinstitute101/
https://www.pharmacologyuniversity.com
https://www.cannabisonlineschool.com

SS UPDATED AND UNCHANGED FROM SEPTEMBER NO DILUTION Restricted Shares all held by insiders and employees which was given through benefit plans and Merger Consideration. Float is only about 1.7 Billion Please See OTC Market Filings

Authorized Shares 20,000,000,000 09/28/2020
Outstanding Shares 8,732,256,416 09/28/2020
Restricted 7,023,693,512 09/28/2020
Unrestricted 1,708,562,904 09/28/2020
Held at DTC 1,380,650,255 09/28/2020
Float 158,562,904 02/28/2019

https://backend.otcmarkets.com/otcapi/company/financial-report/256967/content




Restricted Shares Below

China Infrastructure Construction Corp. (OTCPK: CHNC) is Pleased to Announce its Acquisition of Precision Research Institute, LLC (PRI)
Press Release | 10/21/2019
HOUSTON, TX, Oct. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – China Infrastructure Construction Corp. (OTCPK: CHNC) www.chnc-hdh.com is pleased to announce its acquisition of Precision Research Institute, LLC (PRI).

PRI is a Multi-Therapeutic, Dedicated Research Unit based in Houston, Texas. PRI brings multi-million-dollar contracts with the largest pharmaceutical companies in the world--like Abbvie, Samumed, Gilead, Intercept, Shire Pharmaceuticals, and more. President & CEO Elizabeth Hernandez says, “This acquisition of PRI, our second in the past year, now puts CHNC in the unique position of conducting its own clinical research trials. Which holds an important value the to the future of Medicine. CHNC is now in position to be the leader in the arena of Medical Clinical Trials. CHNC is in the process of becoming its very own Contract Research Organization (CRO) in the Industry. The looking forward to developing the future of Pharmaceutical, Biotechnology, and Pharmacovigilance Clinical Trials. PRI has Phase I, II, and III clinical trial capabilities--a rare feat. PRI’s facility is 4500 sq. ft. and currently has ongoing Phase II, III clinical trials, along with observational studies. Their fifteen active MULTI-MILLION-DOLLAR CONTRACTS is a great head start for CHNC. We look forward to expanding quickly!

The acquisition, which has been approved by the board of directors, is subject to certain closing conditions, including OTC approval, approval by the stockholders of China Infrastructure Construction Corp. (CHNC), minimum cash balance of CHNC at closing, and other customary closing conditions.

About China Infrastructure Construction Corp. (OTCPK: CHNC)

Hippocrates Direct Healthcare, Inc. is a wholly owned subsidiary of CHNC, maintains a medical office, and also does clinical research for pharmaceutical companies. Hippocrates began with its membership-based model and now provides stem cell and clinical research services.

Hippocrates Direct Healthcare, Inc. is a wholly-owned subsidiary of China Infrastructure (OTCPK: CHNC). China Infrastructure's common stock trades on the OTC Markets under the ticker symbol "CHNC."

Safe Harbor Statement

The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "projects," "intends," and similar phrases. Forward-looking statements involve risks and uncertainties that could cause actual results to differ from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of geopolitical conditions, competition, changes in technology and methods of marketing, and various other factors beyond the company's control.

Hippocrates Direct Healthcare™ and the Hippocrates Direct Healthcare™ logo are all trademarks or registered trademarks of Hippocrates Direct Healthcare™, Inc.


CONTACTS:
Investors:
Hippocrates Direct Healthcare™, Inc.
[e-mail]
832-606-7500

Media:
[e-mail]

$CHNC: PharmacologyUniversity - Medicinal Cannabis



www.pharmacologyuniversity.com Powered by $CHNC

Pharmacology University is a company with more than 12 years of experience in educational systems focused on medicinal cannabis. We were born in Texas and since then we have had the challenge of transforming the social stigma of medicinal cannabis with the best tool in the world: Education.






Our educational products and consulting services have reached different states and countries such as Texas, Florida, Arkansas, Nevada, Colorado, Arizona, Washington, California, Hawaii, Puerto Rico, Colombia, Argentina, & Mexico, among others. During this wonderful journey we asked ourselves the question, "does society deserve a complete educational system that will prepare the leaders for this unstoppable industry?" We found the answer. Chronically ill patients need excellent growers, chemists, dispensary technicians, lawyers, doctors and entrepreneurs to help change the archaic cannabis laws and to help them improve the quality of their life. In addition to our seminars and consulting services, we now offer 5-week courses and an intensive master's degree program in cannabis science that will allow us to form and to prepare a group of professionals that will become the next generation of leaders for the medicinal cannabis space.